Market volatility has struck again. Last week, U.S. equities continued their slide in August, leaving many market-watchers wondering whether or not equities in general had reached their peak. The attributed to this precipitous decline in share prices is most likely multi-faceted. There is the Federal Reserve, which still is not sure it will pause on interest rates
0 Comments
Jen-Hsun Huang, CEO, Nvidia David Paul Morris | Bloomberg | Getty Images Check out the companies making headlines in the premarket. Nvidia — The chipmaker popped 7% after reporting another blowout quarter that topped Wall Street’s estimates. Nvidia also offered optimistic guidance, saying that sales will jump 170% during the current period as demand for
0 Comments
Quantum computing, a field that leverages the principles of quantum physics, has been steadily gaining traction over the years. Among the companies vying for dominance in this nascent industry, IonQ (NASDAQ:IONQ) stands out with its unique approach to quantum computing. Despite the compelling story painted by the company, however, investors should tread carefully with IONQ
0 Comments
Earlier this month, I gave readers the rundown on Flexible Solutions International (NYSEAMERICAN:FSI) stock, an under-the-radar “green wave” play. With a low valuation, coupled with the company’s steady growth over the past few years, on the surface FSI stock appeared to be an opportunity worth exploring. After diving into the details, more stood out, suggesting that
0 Comments
Looking for the best value stocks? Tracey Ryniec, Stock Strategist at Zacks Investment Research, discusses two stocks that might be worth a closer look by value investors: Horizon Pharma Plc (HZNP) and Dean Foods (DF). Both companies have forward P/Es well below the average of the S&P 500, which is still a sky-high level of
0 Comments
Artificial intelligence is changing the drug-discovery process by making it much faster and cheaper.  Traditionally, most biotech stock drug candidates fail. Indeed, according to Nature, “An estimated 86% of drug candidates developed between 2000 and 2015 did not meet their stated endpoints.” And the well-respected consulting firm McKinsey reported that “Today, to discover and develop a
0 Comments